Abstract #4189

The Therapy Response Monitoring by DCE-MRI in Primary Liver Cancers

David H. Gultekin^1,2, William R. Jarnagin³, Jason A. Koutcher¹, Mithat Gonen⁴, Dana Haviland³, Leslie H. Blumgart³, Michael I. D'Angelica³, Yuman Fong³, Ronald P. DeMatteo³, Nancy E. Kemeny⁵, Lawrence H. Schwartz²

¹Medical Physics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ²Radiology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ³Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ⁴Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA; ⁵Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

The role of DCE-MRI has been evaluated in a Phase II clinical study for the assessment of response to therapy in patients with unresectable primary liver cancers, hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), undergoing regional chemotherapy through continuous hepatic arterial infusion (HAI) treatment procedure.